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TaiwanMethods: This is a retrospective cohort study based on secondary analysis of prospectively
collected data in the NHI system and governmental data on death registry in Taiwan during
1997e2007. By using the broad and narrow definitions for IPF, we estimated incidence and
prevalence rates of IPF, and its associated clinical outcomes.
Results: The estimates of annual IPF incidence rates became more stable after 2000, ranging
between 0.9 and 1.6 cases per 100,000 persons. The prevalence rates became more than
twofold from 2000 to 2007 (from 2.8 to 6.4 cases per 100,000 persons for the broad definition,
and from 2.0 to 4.9 cases per 100,000 persons for the narrow definition). Men of age older than
75 years had markedly higher incidence and prevalence rates than other groups. Around 40% of
all incidences and about 30% of prevalent cases occurred in this population group. The median
survival time after IPF diagnosis was 0.9 year (interquartile range (IQR), 0.2e2.5 years) and 0.7
year (IQR, 0.1e2.3 years) for the broad and narrow definitions, respectively. Progression of IPF
was the leading cause of death, followed by cancer.
Conclusions: In Taiwan, elderly men were the major group suffering from IPF. Survival time
was short after IPF diagnosis, and the poor survival was largely attributable to quick IPF
progression after diagnosis.
ª 2012 Elsevier Ltd. All rights reserved.Idiopathic pulmonary fibrosis (IPF), characterized anatom-
ically by scarring of the lungs, is one of the most common
entity of interstitial lung disease. It carries a poor prog-
nosis, with a limited option of therapy.1e4 As IPF is rarely
observed, it calls for large-scale population studies to shed
light on features of the disease, such as high-risk demo-
graphic groups and disease burdens.
A retrospective cohort study in the United States during
the period from January 1996 through December 2000 re-
ported prevalence rates ranging from 0.8e1.2 to 64.7e76.4
per 100,000 persons under different criteria for identifying
IPF.5 A British study based on the death registrations and
primary care data showed an overall incidence rate of 7.44
per 100,000 person-years, as well as an increase by 35%
from 2000 to 2008.6 Most epidemiologic studies5e15 of IPF
focused on western communities, including United State,
United Kingdom, Finland, and Norway, that were predom-
inantly Caucasian.
In contrast, little is known in regard to IPF among Asians.
This study took advantage of a large population-based
database of the Taiwan National Health Insurance (NHI)
system to investigate the epidemiology of IPF, so as to help
fill the knowledge gap. It generated estimates for IPF
incidence and prevalence rates in the Taiwan population
from the late 1990s to 2007, and compared the rates among
different age-gender groups. Additional issues explored by
the study included need for mechanical ventilation care,
survival time, and cause of death in the IPF patients.Materials and methods
Study design and setting
This is a retrospective cohort study based on secondary
analysis of prospectively collected data in the NHI system
and governmental data on death registry. It is part of
a research project on respiratory care. The National Health
Research Institutes (NHRI) approved the research project.
The research database contains NHI data and correspondingdeath-certificate data for patients ever receiving any kind
of respiratory care in the NHI. All individual identification
numbers were scrambled by the Bureau of National Health
Insurance (BNHI) for privacy protection. The NHI covers and
protects almost all Taiwanese, and provides medical
services in almost all outpatient visits and hospital admis-
sions.16,17 It is thus appropriate to use the NHI care system
as a research setting for investigating the epidemiology of
IPF in Taiwan.Data sources
Original data for the study were from two Taiwan govern-
mental organizations. The NHI data were from the BNHI,
and data of the national mandatory death registry system
were from the Ministry of the Interior. The NHI database
contains comprehensive claims and registration data. It has
detailed information on health services, procedures and
prescriptions provided in the NHI, and their payments and
times of use. Also included are data on diagnoses for
patients, as well as background information on patients,
physicians and healthcare institutions. Patients’ diagnoses
are coded using the International Classification of Diseases,
Ninth Revision (ICD-9). As the BNHI has been routinely
auditing claims data to prevent fraud in the NHI,18 the
quality of NHI data is generally reliable. Taiwan’s death-
certificate data are also regarded as highly reliable,
because death registry is mandatory in a well-maintained
household registration system.
The NHRI used the original data to construct a longitu-
dinal database for patients who ever used invasive or non-
invasive respiratory care in NHI during 1996e2007. This
cohort included 2,619,534 patients, representing 10% of all
NHI enrollees and 29% of all patients ever using any kind of
respiratory care under NHI in these 12 years. This sampling
fraction (a 3.4:1 ratio) is based on a regulation that limits
the maximal amount of NHI data that can be extracted for
research purposes.
1568 C.-C. Lai et al.Definitions for identifying IPF incidence
This study referred to the Raghu et al. study to formulate
definitions for IPF,5 and focused on patients 18 years of age
or older. For comparison purposes, we formulated both
broad and narrow definitions for IPF. The broad definition
consists of the following three conditions: (1) there was at
least one 1 National Health Insurance (NHI) claim with IPF
diagnosis (ICD-9-CM code: 516.3) between January 1, 1997
and December 31, 2007; (2) for at least one NHI claim with
IPF diagnosis, there was no NHI claim with diagnosis for any
other interstitial lung diseases (ILDs; Appendix 1) since the
day of IPF diagnosis (the time of confirming IPF incidence
was the date of the first NHI claim meeting this condition);
(3) the patient’s age  18 at the time of confirming IPF
incidence.
Because an IPF diagnosis is more reliable if it was based
on appropriate testing, we added a few more conditions to
the broad definition to form a narrow definition. The
conditions for the narrow definitions are as follows: (1) all
conditions for the broad definition were satisfied; (2) for at
least one NHI claim with IPF diagnosis, there was at least
one NHI procedure for surgical lung biopsy, transbronchial
lung biopsy, or computed tomography of the thorax
(Appendix 2) before or on the day of IPF diagnosis (the time
of confirming IPF incidence was “the date of the first NHI
claim meeting this condition,” which might be later than
the time for IPF incidence under the broad definition).
Measures and analyses
We counted the number of patients diagnosed with IPF in
each year during 1997e2007, and calculated the incidence
rate of a year as the number of newly diagnosed patients
per 100,000 persons ever alive in the NHI system in the
year. The prevalence rate was measured as the number of
patients per 100,000 persons alive in the NHI system as of
the end of a year. We conducted such calculations based on
both broad and narrow definitions, and performed the
analyses separately for different age-gender groups.
We further investigated incidence rates of respiratory
exacerbation requiring mechanical ventilation care. The
NHI care covers invasive ventilators, negative pressure
ventilators, and positive pressure ventilators. We focused
on identifying the time of the first incidence of respiratory
exacerbation requiring mechanical ventilation care after
IPF diagnosis. We followed patients who were diagnosed
with IPF, and did not experienced mechanical ventilation
care before the IPF diagnosis. Each patient was followed
until death or the end of 2007. Finally, we examined
survival time after IPF diagnosis, and primary causes of
death among deceased IPF patients.Results
Annual incidence and prevalence rates
Total population number in Taiwan is about 20 million. The
database is a sampling about 1:3.4 so there are about 6
million men women aged 18 yr and older in the studydatabase. Based on the broad case definition, estimated
prevalence ranged from 0.7 per 100,000 in 1998 to 6.4 per
100,000 in 2007; based on the narrow case definition,
estimated prevalence ranged from 0.5 per 100,000 in 1998
to 4.9 per 100,000 in 2007. The incidence was according to
the newly diagnosis cases in that year. According to the
broad case definition, the annual incidence of IPF was
estimated to range from 0.6 per 100,000 in 1998 to 1.4 per
100,000 in 2007; according to the narrow case definition,
the annual incidence of IPF was estimated to range from 0.5
per 100,000 in 1998 to 1.2 per 100,000 in 2007. Both prev-
alence and incidence are increased by year no matter by
the broad or the narrow case definition (Table 1).Comparison of incidence and prevalence rates
among age-gender groups
According to the data in 2007, the prevalence and inci-
dence by age and sex was presented in Table 2. Based on
the broad case definition, estimated prevalence ranged
from 1.6 per 100,000 (age, 18e34 yr) to 75.8 per 100,000
(age  75 yr) in men and from 0.9 per 100,000 (age,
18e34 yr) to 29.9 per 100,000 (age  75 yr) in women.
Based on the narrow case definition, estimated prevalence
ranged from 1.2 per 100,000 (age, 18e34 yr) to 64.3 per
100,000 (age  75 yr) in men and from 0.8 per 100,000 (age,
18e34 yr) to 222.0 per 100,000 (age  75 yr) in women.
According to the broad case definition, the annual inci-
dence of IPF was estimated to range from 0.1 per 100,000
(age, 18e34 yr) to 23.9 per 100,000 (age  75 yr) in men
and from 0.2 per 100,000 (age, 18e34 yr) to 7.3 per 100,000
(age  75 yr) in women. According to the narrow case
definition, the annual incidence of IPF was estimated to
range from 0.1 per 100,000 (age, 18e34 yr) to 21.4 per
100,000 (age  75 yr) in men and from 0.2 per 100,000 (age,
18e34 yr) to 6.0 per 100,000 (age  75 yr) in women. Either
prevalence or incidence was generally higher among aged
people and men.Clinical course and cause of death
Based on broad definition, the rate of IPF-related exacer-
bation was 0.11 per person-year. The frequency was higher
among the initial 2 years up to 0.17 per person-year and
then down to 0.07 (2e4 yr) and 0.05 (>4 yr). Based on
narrow definition, the rate of IPF-related exacerbation was
0.12 per person-year. The frequency was higher among the
initial 2 years up to 0.18 per person-year and then down to
0.08 (2e4 yr) and 0.05 (>4 yr) (Table 3). The survival curve
of the broad definition cases and the narrow definition
cases are showed in Fig. 1. According the broad case defi-
nition, 371 patients died and the primary cause of death
was IPF related in 138 (37.2%). The median year from IPF
diagnosis to death was 0.9 year with interquartile range
0.2e2.5 years. According the narrow case definition, 286
patients died and the primary cause of death was IPF
related in 104 (36.2%) (Table 4). The median year from IPF
diagnosis to death was 0.7 year with interquartile range
0.1e2.3 years.
Table 1 Prevalence and incidence rates of idiopathic pulmonary fibrosis from 1997 to 2007, by case definition.
All cases New cases
Broad definition Narrow definition Broad definition Narrow definition
Prevalence
ratea
Number
of cases
Prevalence
ratea
Number
of cases
Incidence
rateb
Number
of cases
Incidence
rateb
Number
of cases
1997c 0.3 19 0.2 12 0.4 23 0.2 12
1998 0.7 44 0.5 33 0.6 38 0.5 30
1999 1.1 67 0.7 47 0.7 48 0.5 35
2000 1.7 110 1.2 75 0.9 61 0.6 40
2001 2.8 182 2.0 128 1.6 103 1.2 78
2002 3.8 242 2.8 175 1.4 92 1.1 74
2003 4.5 285 3.3 206 1.2 81 0.9 60
2004 5.3 323 3.8 236 1.3 82 1.1 67
2005 5.8 368 4.1 263 1.4 95 1.0 66
2006 6.0 385 4.4 286 1.0 70 0.9 61
2007 6.4 418 4.9 318 1.4 96 1.2 82
a The prevalence rate was measured as the number of patients per 100,000 persons alive in the NHI system as of the end of a year.
b The incidence rate was measured as the number of newly diagnosed patients per 100,000 persons ever alive in the NHI system in
a year.
c As 1997 was the first year under observation, its prevalence rate was no larger than the incidence rate.
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The present work is the first population-based study of IPF
in Taiwan. We had several significant findings different from
the western countries. The estimated prevalence of IPF in
Taiwan ranged from 0.7 to 6.4 per 100,000 populations
based on broad case definition, and ranged from 0.5 to 4.9
per 100,000 populations based on narrow case definition.
The annual incidence is estimated to range from 0.6 to 1.4
per 100,000 populations, and from 0.5 to 1.2 per 100,000
populations based on broad and narrow case definitions,
respectively. Most important of all, both of the prevalenceTable 2 Prevalence and incidence rates of idiopathic pulmonar
All cases
Broad definition Narrow definition
Prevalence
rate1
Number
of cases
Prevalence
ratea
Num
of ca
Men
Age, yr
18e34 1.6 13 1.2 10
35e44 1.3 7 0.8 4
45e54 4.0 20 2.8 14
55e64 10.3 30 8.9 26
65e74 35.1 64 26.3 48
75þ 75.8 112 64.3 95
Women
Age, yr
18e34 0.9 8 0.8 7
35e44 1.3 7 0.9 5
45e54 4.4 22 3.2 16
55e64 12.5 38 10.2 31
65e74 25.9 53 15.2 31
75þ 29.9 42 22.0 31
a The prevalence rate was measured as the number of patients per
b The incidence rate was measured as the number of newly diagno
2007.and incidence is increasing during the study period, irre-
spective of the case definition.
While compared with previous studies in western
country,5,6,11e15 the overall incidence and prevalence of IPF
in Taiwan is relative lower than other countries. The
epidemiological studies of IPF in western countries re-
ported the estimated prevalence range from 2 to 29 per
1000,000 population, respectively.11e13 The lower preva-
lence or incidence in Taiwan may be due to different study
methods or due to ethnic difference. Because the similar
large-scale epidemiologic study in Asia is limited, further
study in Asia is needed to confirm the racial difference. Iny fibrosis in 2007, by age, sex and case definition.
New cases
Broad definition Narrow definition
ber
ses
Incidence
rateb
Number
of cases
Incidence
rateb
Number
of cases
0.1 1 0.1 1
0.4 2 0.2 1
0.6 3 0.6 3
3.0 9 2.3 7
3.7 7 3.7 7
23.9 38 21.4 34
0.2 2 0.2 2
0.2 1 0.2 1
0.2 1 0.2 1
1.9 6 1.6 5
6.7 14 5.3 11
7.3 11 6.0 9
100,000 persons alive in the NHI system as of the end of 2007.
sed patients per 100,000 persons ever alive in the NHI system in
Table 3 The first incidence of respiratory exacerbation requiring mechanical ventilation care after diagnosis of IPF.a
Time after IPF diagnosis
Of all time lengths 0e2 years 2e4 years >4 years
Sample meeting the broad definitionb
Number of person-years in the follow-up 2107.7 980.7 595.9 531.1
Number of first-ever cases after IPF diagnosis 241 168 44 29
Incidence rate (number of cases per person-year) 0.11 0.17 0.07 0.05
Sample meeting the narrow definitionc
Number of person-years in the follow-up 1538.5 731.4 434.9 372.3
Number of first-ever cases after IPF diagnosis 187 134 35 18
Incidence rate (number of cases per person-year) 0.12 0.18 0.08 0.05
a IPF: idiopathic pulmonary fibrosis.
b Subjects in the follow-up were 712 patients who were diagnosed with IPF of the broad definition during 1997e2007, and did not
experienced mechanical ventilation care before the IPF diagnosis. Each patient was followed until death or the end of 2007, with
a follow-up length ranging from 0.003 to 10.98 years, and a median of 2.27 years.
c Subjects in the follow-up were 550 patients who were diagnosed with IPF of the narrow definition during 1997e2007, and did not
experienced mechanical ventilation care before the IPF diagnosis. Each patient was followed until death or the end of 2007, with
a follow-up length ranging from 0.003 to 10.55 years, and a median of 2.11 years.
1570 C.-C. Lai et al.contrast to the difference incidence and prevalence of IPF
between our study and previous studies,5,6,11e13 the rising
trend of IPF in Taiwan is in consistent with previous
studies.5,6,10
Age was a significant effect modifier in present work; we
observe an effect modification by age with the highest
incidence and prevalence noted at the oldest age of > 75
years (Table 2) irrespective of sex or case definition. This is
consistent with previous study in UK,10 the crude incidence
rate of IPF was highest in age of 75e84.9 years. When we
investigate the gender difference, we noted that the inci-
dence and prevalence of IPF is relative higher in men than
women, and the effect is strongest in the elderly group. In
the UK study,6 the crude incidence rate of IPF was signifi-
cant higher in male than in female 9.46 per 100,000 person-
years versus 5.46 per 100,000 person-years, P < 0.001). In
another population study from the county of Bernalillo,
New Mexico, the incidence of IPF was estimated at 10.7 and
7.4 cases per 100,000 per year for men and female,
respectively.13 In summary, IPF most commonly develops in
elderly men in Taiwan, which is similar with western
country.
Previous studies had demonstrated that IPF will lead to
respiratory failure and death at a median of 3 years after
diagnosis.2,19 In Taiwan, this study provides a population-
based estimate on rate of respiratory exacerbations
needing ventilator in patients with IPF. Most of episodes of
respiratory exacerbation developed within 2 year after
diagnosis of IPF. Furthermore, this study investigates the
mortality rate of death in patients with IPF. Most of the
mortality develops soon after diagnosis, and the median
year from IPF diagnosis to death was 0.9 year (IQR: 0.2e2.5
years) based on broad case definitions or 0.7 year (IQR:
0.1e2.3 years) based on narrow case definitions. In
contrary to a recent population-based study in United
State, the median survival for broad- and narrow-case
criteria was 4.37 years and 4.37 years, respectively.4 The
shorter survival in Taiwan may be partly due to the relative
delayed diagnosis that most of the patients had their
diagnosis of IPF in the late stage. This issue is important for
improving the care of quality of patients with IPF, becausea delay in receiving an accurate diagnosis might be asso-
ciated with a higher mortality rate in IPF, which could be
attributed to delay institution of standard therapies, such
as supplemental oxygen, and delay appropriate access to
clinical trials and lung transplantation evaluation.20
The most common primary cause of death in IPF in this
study is progression of IPF, which compromised 36e46% of
mortality, and followed by cancer. It is consistent with
previous study that the primary cause of death was the
progression of IPF (39%), followed by cardiovascular disease
(27%), lung cancer (10%), pulmonary embolism (3%),
pulmonary infection (3%).21 In Asia, the results are
different. In Korean, Jeon et al reported IPF progression in
68%, followed by infection (14%), lung cancer (8%),
pulmonary embolism (2%), and cardiovascular disease
(2%).22 The similar finding was noted in Japan, Nagai et al
showed that progression of IPF cause 72% death, followed
by lung cancer (13%) and pulmonary infection (8%).23 The
ethnic difference may be the explanation and every site
should establish its own epidemiology.
Our study has several strengths. First, it is population
based with a large nationally sample from the NHI database,
which included outpatients and inpatients, and we caught
the diagnoses from both sources. The use of medical record
also reduced the potential bias related to self-reporting.
Therefore, it is highly representative with little possibility of
recall and selection bias. Second, we take the advantage of
using insurance claim datasets in clinical research is easy
access to the longitudinal records of a large sample of
patients from different geographic areas. By using medical
records, we also reduced potential bias related to self-
reporting. In addition, the likelihood of non-response and
follow-up loss of cohort member was decreased. Therefore,
our study stands alone in its capacity to draw upon an
extensive, nationwide, population-based database, and it
carries the potential for generalization to the population as
a whole and to populations similar to Taiwan.
There are several limitations of our study. First, the NHIRD
lacks detailed clinical informationand thereforedid not allow
us todifferentiate studyparticipantsaccording to the severity
of IPF when it was initially diagnosed, which might limit
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Figure 1 The KaplaneMeier curves for survival after IPF diagnosis (A) The sample of IPF patients meeting the broad definition (B)
The sample of IPF patients meeting the narrow definition.
Idiopathic pulmonary fibrosis in Taiwan 1571specific interpretations of the study results. Second, the
exacerbation of IPF was derived from the first use of
mechanical ventilators in this study, because the information
about the use of mechanical ventilator is confirmatory in the
NHI system. However, since not all IPF require mechanical
ventilation, this would probably underestimate the actual
prevalence/incidence of the events.In conclusion, this first population-based study in Taiwan
demonstrated the secular trend of IPF is increasing in
Taiwan in spite of relatively lower incidence and preva-
lence of IPF in Taiwan than in western countries. Although
the cause of death of patients with IPF in Taiwan is not the
same with western countries, IPF remains a deadly disease
around the world.
Table 4 Primary causes of death among deceased patients of IPFa, by case definition.
Broad definition cases: Survival time after IPF diagnosis
Cause of death <4 weeks % 4e52 weeks % 52 weeks % Total %
Progression of IPF 28 46.7 44 33.8 66 36.5 138 37.2
Pneumonia 5 8.3 12 9.2 9 5.0 26 7.0
Tuberculosis 3 5.0 4 3.1 3 1.7 10 2.7
Sepsis 3 5.0 1 0.8 4 2.2 8 2.2
Respiratory system cancer 4 6.7 13 10.0 22 12.2 39 10.5
Extra-respiratory system cancer 6 10.0 15 11.5 18 9.9 39 10.5
Diabetes 1 1.7 4 3.1 8 4.4 13 3.5
Cardiac disease 3 5.0 17 13.1 16 8.8 36 9.7
Cerebrovascular accident 1 1.7 2 1.5 7 3.9 10 2.7
Other neurologic disease 2 3.3 3 2.3 8 4.4 13 3.5
Renal disease 1 1.7 4 3.1 4 2.2 9 2.4
Liver disease 1 1.7 3 2.3 2 1.1 6 1.6
Gastrointestinal system disease 0 0.0 5 3.8 6 3.3 11 3.0
Others 2 3.3 3 2.3 8 4.4 13 3.5
Total number of deaths 60 130 181 371
Narrow definition cases: Survival time after IPF diagnosis
Cause of death <4 weeks % 4e52 weeks % 52 weeks % Total %
Progression of IPF 21 42.9 35 32.7 48 36.6 104 36.2
Pneumonia 4 8.2 9 8.4 9 6.9 22 7.7
Tuberculosis 2 4.1 3 2.8 2 1.5 7 2.4
Sepsis 3 6.1 1 0.9 3 2.3 7 2.4
Respiratory system cancer 4 8.2 13 12.2 15 11.5 32 11.2
Extra-respiratory system cancer 5 10.2 15 14.0 11 8.4 30 10.5
Diabetes 0 0.0 2 1.9 4 3.1 6 2.1
Cardiac disease 3 6.1 13 12.1 13 9.9 29 10.1
Cerebrovascular accident 1 2.0 1 0.9 6 4.6 8 2.8
Other neurologic disease 2 4.1 3 2.8 7 5.3 12 4.2
Renal disease 0 0.0 4 3.7 2 1.5 6 2.1
Liver disease 1 2.0 3 2.8 2 1.5 6 2.1
Gastrointestinal system disease 1 2.0 3 2.8 4 3.1 8 2.8
Others 2 4.1 2 1.9 5 3.8 9 3.1
Total number of deaths 49 107 131 286
a IPF: idiopathic pulmonary fibrosis.
ICD-9-CM code Description
135 Sarcoidosis
237.7 Neurofibromatosis
272.7 Lipidoses
277.3 Amyloidosis
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(continued on next page)Appendix A. Supplementary material
Supplementary data associated with this article can be
found, in the online version, at http://dx.doi.org/10.1016/
j.rmed.2012.07.012.Appendix 1. ICD-9-CM codes for interstitial
lung diseases (ILDs) other than idiopathic
pulmonary fibrosis (IPF).
(continued )
ICD-9-CM code Description
500 Coal workers’ pneumoconiosis
501 Asbestosis
502 Pneumoconiosis due to other silica
or silicates
503 Pneumoconiosis due to
other inorganic dust
504 Pneumoconiosis due to inhalation
of other dust
505 Pneumoconiosis, unspecifed
506.4 Chronic respiratory conditions due
to fumes or vapors
508.1 Chronic and other
pulmonary manifestations due to radiation
508.8 Respiratory conditions due
to other specified external agents
515 Postinflammatory pulmonary fibrosis
516 Pulmonary alveolar proteinosis
516.1 Idiopathic pulmonary
hemosiderosis
516.2 Pulmonary alveolar microlithiasis
516.8 Other specified alveolar
and parietoalveolar pneumonopathies
516.9 Unspecified alveolar and
parietoalveolar pneumonopathies
517.2 Lung involvement in systemic sclerosis
517.8 Lung involvement in other diseases
classified elsewhere
518.3 Pulmonary eosinophilia
555 Regional enteritis
710 Systemic lupus erythematosus
710.1 Systemic sclerosis
710.2 Sjogren’s disease
710.3 Dermatomyositis
710.4 Polymyositis
714.81 Rheumatoid lung
720 Ankylosing spondylitis
759.5 Tuberous sclerosis
(continued )
NHI code
of medical order Description
33103B Computered tomography
(C. T.) guide biopsy
51027B Excision biopsy-normal
51028B Excision biopsy-special
56015B Pleural biopsy
92021B Biopsy, soft tissue
92022B Biopsy, hard tissue
92067B Biopsy for precancerous
lesion, soft tissue
92068B Biopsy for precancerous
lesion, hard and soft tissue
67051B Thoracoscopic wedge or
partial resection of the Lung
25004C Surgical pathology, level IV
28006C Bronchoscopy
33070B Computered tomography
(C. T.) e without contrast
33071B Computered tomography
(C. T.) e with contrast
33072B Computered tomography
( C. T.) e with/without contrast
33090B Low osmolarity or nonionic
contrast
Idiopathic pulmonary fibrosis in Taiwan 1573Appendix 2. Procedures for diagnosing lung
diseases.NHI code
of medical order
Description
15020B Imprint bronchial biopsy
19007B Ultrasonic guidance
for needle placement
(eg, biopsy, aspiration,
injection)
25009B Muscle biopsy
28009B Thoracoscopy with biopsy
28026B Mediastinoscopy with biopsy
28030C Endoscopic biopsyConflict of interest statement
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